An approach to produce thousands of single-chain antibody variants on a SPR biosensor chip for measuring target binding kinetics and for deep characterization of antibody paratopes

Abstract excerpt

Drug discovery continues to face a staggering 90% failure rate, with many setbacks occurring during late-stage clinical trials. To address this challenge, there is an increasing focus on developing and evaluating new technologies to enhance the “design” and “test” phases of antibody-based drugs (e.g., monoclonal antibodies, bispecifics, CAR-T therapies, ADCs) and biologics during early preclinical development, wit...

Topics

Open a Topic to create a Post that cites this publication.

• Antibodies, Neutralizing
• Antibody Affinity
• Antigens
• Complementarity Determining Regions
• High-Throughput Nucleotide Sequencing
• Immunoglobulin Fab Fragments
• Monoclonal and Polyclonal Antibodies Research
• Mutation

Identifiers and source

Literature Corpus work

626d606a-ab96-517e-a6fe-0c54bca38630

DOI

10.1101/2025.01.11.632576